GRPR and breast carcinoma: The agent was shown to be taken up into PCa PC3 and breast cancer MCF7 and MDA-MB231 cells to a significantly higher extent than the monospecific GRPR-targeting reference peptide (up to fivefold after 24 h) [94] and further to be able to enter the nucleus [95].